SEC 13F Intelligence

Octagon Capital Advisors LP / DNTH

Octagon Capital Advisors LP’s Dianthus Therapeutics Inc Position

Does Octagon Capital Advisors LP own Dianthus Therapeutics Inc (DNTH)? Yes — 1.95M shares worth $163M (+18.08% of its 13F portfolio) as of Q1 2026, down from 2.42M shares the prior filed quarter.

Position Value
$163M
Q1 2026
Shares
1.95M
% of Portfolio
+18.08%
Quarters Held
11
currently held

Position History DNTH

Reported value by quarter
Q3 ’23: $7MQ3 ’23Q4 ’23: $6MQ1 ’24: $41MQ1 ’24Q2 ’24: $45MQ3 ’24: $48MQ3 ’24Q4 ’24: $46MQ1 ’25: $42MQ1 ’25Q2 ’25: $44MQ3 ’25: $95MQ3 ’25Q4 ’25: $100MQ1 ’26: $163MQ1 ’26filingsflow.com
QuarterSharesValue% of Portfolio
Q1 20261.95M$163M+18.08%
Q4 20252.42M$100M+12.09%
Q3 20252.42M$95M+14.41%
Q2 20252.34M$44M+9.57%
Q1 20252.34M$42M+8.22%
Q4 20242.11M$46M+7.57%
Q3 20241.75M$48M+7.44%
Q2 20241.75M$45M+7.10%
Q1 20241.38M$41M+4.96%
Q4 2023554.0K$6M+0.92%
Q3 2023480.0K$7M+1.01%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Octagon Capital Advisors LP’s full portfolio or all institutional holders of DNTH.